Abstracts tagged "glucocorticoids and vasculitis"

Abstract Number: 2788 • 2018 ACR/ARHP Annual Meeting
The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-Induction for Treatment of Severe ANCA-Associated Vasculitis
Michael Walsh¹, Peter A. Merkel² and David Jayne³, ¹Nephrology, McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: It is uncertain whether plasma exchange improves clinical outcomes in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Also uncertain is whether, compared to standard therapy with…
Abstract Number: 980 • 2016 ACR/ARHP Annual Meeting
Short-Course Glucocorticoids in ANCA-Associated Vasculitis: A Proof of Concept Study
Eli Miloslavsky¹, John Niles², Karen Laliberte², Katherine Cosgrove² and John H. Stone³, ¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Despite therapeutic advances in ANCA-associated vasculitis (AAV), patients continue to be exposed to considerable treatment morbidity from long-term glucocorticoid (GC) use. The optimal duration…
Abstract Number: 2971 • 2016 ACR/ARHP Annual Meeting
Characteristics and Management of IgA Vasculitis (Henoch-Schönlein purpura) in Adults: Data from the 260 Patients Included in the Igavas Survey
Alexandra Audemard-Verger¹, Evangeline Pillebout², Agnès Dechartres³, Johan Chanal⁴, Zahir Amoura⁵, Noemie Le Gouellec⁶, Patrice Cacoub⁷, Noémie Jourde-Chiche⁸, Geoffroy Urbanski⁹, Jean-Francois Augusto⁹, Guillaume Moulis¹⁰, Loic Raffray¹¹, Alban Deroux¹², Aurélie Hummel¹³, Bertrand Lioger¹⁴, Melanie Catroux¹⁵, Stanislas Faguer¹⁶, Julie Goutte¹⁷, Nihal Martis¹⁸, Francois Maurier¹⁹, Etienne Riviere²⁰, Sébastien Sanges²¹, Aurélie Baldolli²², Nathalie Costedoat-Chalumeau²³, Melanie Roriz²⁴, Xavier Puéchal²⁵, Marc Andre²⁶, Christian Lavigne²⁷, Boris Bienvenu²⁸, Arsène Mékinian²⁹, Elie Zagdoun³⁰, Charlotte Girard³¹, Alice Berezne³², Loïc Guillevin²⁵, Eric Thervet³³ and Benjamin Terrier³⁴, ¹Internal Medicine, Caen, France, ²Nephrology, Saint Louis, Paris, France, ³Epidemiology, Hotel Dieu, Paris, France, ⁴Dermatology, Cochin Hospital, Paris, France, ⁵Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁶Internal Medicine, Lille, France, ⁷Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d’Immunologie clinique, DHU i2B, Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ⁸Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ⁹Internal Medicine, CHU, Angers, France, ¹⁰CHU Purpan, Toulouse, France, ¹¹Internal Medicine, CHU de Bordeaux, Bordeaux, France, ¹²Internal Medicine, CHU Grenoble, Grenoble, France, ¹³Necker, paris, France, ¹⁴GICC UMR 7292, University François Rabelais, Tours, France, ¹⁵Internal Medicine, Cochin Hospital, Paris, France, ¹⁶Nephrology, CHU, Toulouse, France, ¹⁷Internal Medicine, CHU, Paris, France, ¹⁸Internal Medicine, CHU, Nice, France, ¹⁹Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ²⁰Internal Medicine, CHU, Bordeaux, France, ²¹Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ²²Internal Medicine, CHU, Caen, France, ²³Internal Medicine, Cochin University Hospital, Paris, France, ²⁴internal Medicine, Lariboisière, Paris, France, ²⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²⁶Internal Medicine CHU G Montpied, Internal Medicine, Clermont Ferrand, France, ²⁷CHU Angers, department of Internal Medicine, Angers, France, ²⁸Caen University Hospital, Caen, France, ²⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ³⁰Internal Medicine, CH, Saint-Lo, France, ³¹Internal Medicine, CHU, Lyon, France, ³²Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ³³Nephrology, Hopital Européen Georges Pompidou, APHP, PARIS, France, ³⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: We analyzed data from 260 patients with IgAV included in a French multicenter retrospective IGAVAS survey. Results: Mean age at diagnosis was 50.1±18 years,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].